UNSPSC 51422501: Isoprednidene

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4G6A72XC0I, chemically known as 11beta,17,21-trihydroxy-16-methylenepregna-4,6-diene-3,20-dione but generally known as isoprednidene, which bears US NIH Compound Identifier 71888. European Medicines Agency schedules Isoprednidene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08329MIG. The term ISOPREDNIDENE is an International Non-Proprietary Name.

UNSPSC 51422501 Isoprednidone is a Commodity code nominally covering a specific pharmaceutical compound, yet the recent state and local opportunities tagged under this code show minimal direct relevance to the code's stated scope. Seminole County, Florida issued IFB 60459723LAS seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for community health initiatives, with quarterly deliveries to the Seminole County Community Health Building and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on vendors' capacity to implement a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting capabilities outside traditional pharmacy benefit manager and group purchasing organization relationships. Neither opportunity directly addresses isoprednidone procurement; Seminole County's solicitation centers on opioid-reversal and drug-disposal products, while the Texas HHS RFI explores pharmacy benefit program restructuring at the administrative level.

Issuing bodies across the recent opportunities span county health authorities and state health commissions, though the code shows limited transaction volume and no clear pattern of repeat buyers. Geographically, activity appears concentrated in Florida and Texas based on the two identified opportunities, though the code's sparse recent record suggests limited statewide or multi-jurisdictional procurement momentum. The mismatch between the code's nominal pharmaceutical scope and the actual work being solicited—neither opportunity targets isoprednidone or related corticosteroid compounds—indicates that this code may not reflect current state and local buying patterns, and firms evaluating pursuit should verify alignment with specific solicitations rather than relying on the code label alone.